Ponvory Approved in EU for Active Relapsing Forms of MS

Ponvory Approved in EU for Active Relapsing Forms of MS

294975

Ponvory Approved in EU for Active Relapsing Forms of MS

The European Commission has approved Ponvory (ponesimod) to treat adults with relapsing forms of multiple sclerosis (MS) and active disease, as defined by clinical or imaging features. The approval, which follows a recommendation from the Committee for Medicinal Products for Human Use in March, covers clinically isolated syndrome, relapsing-remitting MS (RRMS), and active secondary progressive MS (SPMS). A similar approval was also recently granted to Ponvory in the U.S. The treatment is taken as a 20 mg tablet, once daily,…

You must be logged in to read/download the full post.